JPRN-UMIN000003477已完成2 期
Randomized phase 2 study of mFOLFOX6 plus bevacizumab versus modified OPTIMOX plus bevacizumab for metastatic colorectal cancer - Randomized phase 2 study of mFOLFOX6 plus bevacizumab versus modified OPTIMOX plus bevacizumab for metastatic colorectal cancer
Chiba Cancer Center Hospital0 个研究点目标入组 80 人开始时间: 2010年4月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) contraindication to 5-FU, oxaliplatin, UFT, calcium folinate, or bevacizumab. 2) moderate/severe pleural effusion, ascites or pericardial effusion. 3) brain metastases. 4) history of active other malignancies. 5) neuropathy. 6) history of thoromboembolitic disease. 7) uncontrollable Diabetes Mellitus or hypertension 8) interstitial lung disease, pulmonary fibrosis or severe pulmonary emphysema. 9) intestinal bleeding, ileus, bowel obstruction or uncontrolled peptic ulcer. 10) clinically significant infectious disease (body temperature more than 38.0 degrees) 11) urinary protein (more than 1+) 12) uncontrolled watery diarrhea. 13) pregnant or lactating women, women who are capable of pregnancy or intend to get pregnant. 14) Any other cases who are regarded as inadequate for study enrollment by the attending doctors.
研究者
相似试验
已完成
2 期
Randomized phase ll study of mFOLFOX6 + bevacizumab or mFOLFOX6+cetuximabin liver only metastasis from KRAS wild type colorectal cancerJPRN-UMIN000010209EPS Corporation120
已完成
3 期
Randomized phase III study of FOLFOX plus bevacizumab versus FOLFIRI plus bevacizumab for metastatic colorectal cancermetastatic colorectal cancerJPRN-UMIN000001396West Japan Oncology Group400
已完成
2 期
Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver MetastasesLiver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal CancerNCT01836653EPS Corporation122
进行中（未招募）
1 期
folfoxiri plus bevacizumab plus atezolizumab or folfoxiri plus bevacizumab nel carcinoma del colonretto metastatico.Metastatic Colorectal CancerMedDRA version: 21.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2017-000977-35-ITG.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST201
已完成
2 期
Randomized phase II study of mFOLFOX6 versus TS-1/CPT-11 in patients with advanced/recurrent colorectal cancerPatients with advanced and/or recurrent colorectal cancerJPRN-UMIN000000786OGSG70